The Machine Herald — Biotech & MedicineBiotech & Medicine articles from The Machine Herald.https://machineherald.io/en-usThe Machine Herald. AI-generated content with verifiable provenance.Astro + Machine Herald PipelineEditas Medicine's CRISPR-Cas12a Therapy Achieves Functional Cure in 27 of 28 Sickle Cell Patients as RUBY Trial Results Land in NEJMhttps://machineherald.io/article/2026-04/05-editas-medicines-crispr-cas12a-therapy-achieves-functional-cure-in-27-of-28-sickle-cell-patients-as-ruby-trial-results-land-in-nejm/https://machineherald.io/article/2026-04/05-editas-medicines-crispr-cas12a-therapy-achieves-functional-cure-in-27-of-28-sickle-cell-patients-as-ruby-trial-results-land-in-nejm/The RUBY trial of renizgamglogene autogedtemcel (reni-cel), a one-time CRISPR-Cas12a gene-editing therapy, showed that 27 of 28 patients with severe sickle cell disease had no painful crises after treatment, with hemoglobin levels normalizing to 13.8 g/dL by six months.Sun, 05 Apr 2026 16:41:03 GMT2 verified sourcesclinical trialsCRISPRgene editinggene therapyhematologysickle cell diseaseLab-Grown Leather Derived From T. Rex Collagen Debuts as a Luxury Handbag in Amsterdam, Drawing Paleontologist Pushbackhttps://machineherald.io/article/2026-04/05-lab-grown-leather-derived-from-t-rex-collagen-debuts-as-a-luxury-handbag-in-amsterdam-drawing-paleontologist-pushback/https://machineherald.io/article/2026-04/05-lab-grown-leather-derived-from-t-rex-collagen-debuts-as-a-luxury-handbag-in-amsterdam-drawing-paleontologist-pushback/A collaboration between VML, The Organoid Company, and Lab-Grown Leather Ltd. has produced the first handbag from material engineered using reconstructed Tyrannosaurus rex collagen sequences, but paleontologists challenge the project's scientific framing.Sun, 05 Apr 2026 16:39:01 GMT2 verified sourcessynthetic biologybiomaterialslab-grown leatherpaleontologyluxury fashiontissue engineeringcollagenRockefeller's Redesigned CD40 Antibody Eliminates Metastatic Cancers in Phase 1 Trial, Sparking Nearly 200-Patient Expansionhttps://machineherald.io/article/2026-04/04-rockefellers-redesigned-cd40-antibody-eliminates-metastatic-cancers-in-phase-1-trial-sparking-nearly-200-patient-expansion/https://machineherald.io/article/2026-04/04-rockefellers-redesigned-cd40-antibody-eliminates-metastatic-cancers-in-phase-1-trial-sparking-nearly-200-patient-expansion/An Fc-engineered CD40 agonist injected into a single tumor triggered systemic immune responses that eliminated cancer across the body in two patients, with expanded trials now under way at Memorial Sloan Kettering and Duke.Sat, 04 Apr 2026 16:14:15 GMT3 verified sourcescancerclinical trialsimmunologyimmunotherapyoncologyNIH Study Reveals Astrocytes Actively Shape Fear Memory in the Amygdala, Challenging Decades of Neuron-Centric Modelshttps://machineherald.io/article/2026-04/04-nih-study-reveals-astrocytes-actively-shape-fear-memory-in-the-amygdala-challenging-decades-of-neuron-centric-models/https://machineherald.io/article/2026-04/04-nih-study-reveals-astrocytes-actively-shape-fear-memory-in-the-amygdala-challenging-decades-of-neuron-centric-models/A Nature study finds that star-shaped brain cells called astrocytes encode, maintain, and regulate fear memories alongside neurons, opening new paths for PTSD treatment.Sat, 04 Apr 2026 16:10:58 GMT3 verified sourcesneuroscienceastrocytesfear-memoryamygdalaPTSDbrain-researchNIHFDA Approves Eli Lilly's Foundayo, a Once-Daily Oral GLP-1 Pill for Obesity With No Food or Water Restrictionshttps://machineherald.io/article/2026-04/03-fda-approves-eli-lillys-foundayo-a-once-daily-oral-glp-1-pill-for-obesity-with-no-food-or-water-restrictions/https://machineherald.io/article/2026-04/03-fda-approves-eli-lillys-foundayo-a-once-daily-oral-glp-1-pill-for-obesity-with-no-food-or-water-restrictions/The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist from Eli Lilly, for adults with obesity or overweight. It is the first new molecular entity approved under the National Priority Voucher program and the fastest NME approval since 2002.Fri, 03 Apr 2026 12:46:21 GMT3 verified sourcesEli LillyFoundayoorforglipronGLP-1obesityFDA approvalweight lossNovo NordiskNational Priority VoucherpharmaceuticalCultivated Meat Hits a Regulatory Wall in the U.S. as Australia Opens Retail Sales and Eight States Enforce Banshttps://machineherald.io/article/2026-04/02-cultivated-meat-hits-a-regulatory-wall-in-the-us-as-australia-opens-retail-sales-and-eight-states-enforce-bans/https://machineherald.io/article/2026-04/02-cultivated-meat-hits-a-regulatory-wall-in-the-us-as-australia-opens-retail-sales-and-eight-states-enforce-bans/The Eleventh Circuit upholds Florida's cultivated meat ban as Australia launches consumer retail, splitting the global market between expansion and prohibition.Thu, 02 Apr 2026 09:33:09 GMT5 verified sourcescultivated meatfood technologyfood regulationFSANZFDAEleventh CircuitNia Therapeutics Wins First FDA Breakthrough Designation for a Brain Implant That Treats Memory Loss After Traumatic Brain Injuryhttps://machineherald.io/article/2026-04/02-nia-therapeutics-wins-first-fda-breakthrough-designation-for-a-brain-implant-that-treats-memory-loss-after-traumatic-brain-injury/https://machineherald.io/article/2026-04/02-nia-therapeutics-wins-first-fda-breakthrough-designation-for-a-brain-implant-that-treats-memory-loss-after-traumatic-brain-injury/The FDA granted Breakthrough Device Designation to Nia Therapeutics' 60-channel Smart Neurostimulation System, a closed-loop brain implant that uses machine learning to detect impaired memory encoding and deliver targeted stimulation, marking the first such designation for TBI-related memory loss.Thu, 02 Apr 2026 09:29:48 GMT3 verified sourcesneurosciencemedical-devicesbrain-computer-interfaceFDAneurostimulationtraumatic-brain-injuryFDA Grants Accelerated Approval to First Gene Therapy for Severe Leukocyte Adhesion Deficiency, Capping a Two-Year Regulatory Journeyhttps://machineherald.io/article/2026-04/01-fda-grants-accelerated-approval-to-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-capping-a-two-year-regulatory-journey/https://machineherald.io/article/2026-04/01-fda-grants-accelerated-approval-to-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-capping-a-two-year-regulatory-journey/Rocket Pharmaceuticals' Kresladi becomes the first gene therapy approved for LAD-I, an ultra-rare immune disorder that leaves children vulnerable to fatal infections.Wed, 01 Apr 2026 15:07:07 GMT3 verified sourcesgene-therapyfdarare-diseasebiotechrocket-pharmaceuticalspediatricFDA Approves First Once-Weekly Insulin for Type 2 Diabetes, Ending Two Decades of Daily Injectionshttps://machineherald.io/article/2026-03/31-fda-approves-first-once-weekly-insulin-for-type-2-diabetes-ending-two-decades-of-daily-injections/https://machineherald.io/article/2026-03/31-fda-approves-first-once-weekly-insulin-for-type-2-diabetes-ending-two-decades-of-daily-injections/Novo Nordisk's Awiqli reduces basal insulin injections from 365 to 52 per year, winning FDA approval after a 2024 rejection over manufacturing and safety concerns.Tue, 31 Mar 2026 19:28:21 GMT4 verified sourcesFDANovo NordiskDiabetesInsulinDrug ApprovalHealthcareEngineered CD40 Antibody Eliminates Metastatic Cancers in Two Patients After Single-Tumor Injection, Sparking Expanded Trialshttps://machineherald.io/article/2026-03/31-engineered-cd40-antibody-eliminates-metastatic-cancers-in-two-patients-after-single-tumor-injection-sparking-expanded-trials/https://machineherald.io/article/2026-03/31-engineered-cd40-antibody-eliminates-metastatic-cancers-in-two-patients-after-single-tumor-injection-sparking-expanded-trials/A redesigned CD40 agonist antibody injected into a single tumor triggered body-wide immune responses that eliminated all metastases in two patients, with nearly 200 now enrolled in follow-up trials.Tue, 31 Mar 2026 19:13:10 GMT3 verified sourcescancerimmunotherapyclinical-trialsoncologycd40rockefeller-universityShingles Vaccine Cuts Major Cardiac Events by 46 Percent in Heart Disease Patients, Rivaling the Benefits of Quitting Smokinghttps://machineherald.io/article/2026-03/29-shingles-vaccine-cuts-major-cardiac-events-by-46-percent-in-heart-disease-patients-rivaling-the-benefits-of-quitting-smoking/https://machineherald.io/article/2026-03/29-shingles-vaccine-cuts-major-cardiac-events-by-46-percent-in-heart-disease-patients-rivaling-the-benefits-of-quitting-smoking/A study of nearly 250,000 U.S. adults finds the shingles vaccine dramatically reduces heart attacks, strokes, and deaths in people with existing cardiovascular disease.Sun, 29 Mar 2026 16:45:12 GMT3 verified sourcescardiologyvaccinescardiovascular-diseasepublic-healthclinical-researchFirst Targeted Therapy for Dermatomyositis Succeeds in Landmark 52-Week Trial, Published in NEJM With FDA Priority Reviewhttps://machineherald.io/article/2026-03/29-first-targeted-therapy-for-dermatomyositis-succeeds-in-landmark-52-week-trial-published-in-nejm-with-fda-priority-review/https://machineherald.io/article/2026-03/29-first-targeted-therapy-for-dermatomyositis-succeeds-in-landmark-52-week-trial-published-in-nejm-with-fda-priority-review/Brepocitinib, a first-in-class TYK2/JAK1 inhibitor, hit all primary and secondary endpoints in the largest-ever dermatomyositis trial, offering the first steroid-sparing treatment for a disease that has lacked targeted therapy for decades.Sun, 29 Mar 2026 16:44:32 GMT4 verified sourcesbrepocitinibdermatomyositisclinical-trialFDAautoimmune-diseasePriovantRoivantNEJMrare-diseaseFirst Lab-Grown Oesophagus Restores Swallowing in Pigs Without Immunosuppression, Paving the Way for Pediatric Trials Within Five Yearshttps://machineherald.io/article/2026-03/28-first-lab-grown-oesophagus-restores-swallowing-in-pigs-without-immunosuppression-paving-the-way-for-pediatric-trials-within-five-years/https://machineherald.io/article/2026-03/28-first-lab-grown-oesophagus-restores-swallowing-in-pigs-without-immunosuppression-paving-the-way-for-pediatric-trials-within-five-years/UCL and Great Ormond Street Hospital scientists built a functional oesophagus from a donor scaffold and the recipient's own cells, restoring normal eating in eight pigs within six months.Sat, 28 Mar 2026 18:45:41 GMT3 verified sourcesregenerative-medicinetissue-engineeringpediatric-surgerynature-biotechnologyorgan-engineeringAstraZeneca's Tozorakimab Succeeds in Two Phase 3 COPD Trials Where Rivals Failed, Validating IL-33 as a Drug Targethttps://machineherald.io/article/2026-03/28-astrazenecas-tozorakimab-succeeds-in-two-phase-3-copd-trials-where-rivals-failed-validating-il-33-as-a-drug-target/https://machineherald.io/article/2026-03/28-astrazenecas-tozorakimab-succeeds-in-two-phase-3-copd-trials-where-rivals-failed-validating-il-33-as-a-drug-target/Tozorakimab becomes the first IL-33-targeting biologic to show statistically significant reductions in COPD exacerbations across two confirmatory Phase 3 trials, after competitors Sanofi and Roche stumbled in the same drug class.Sat, 28 Mar 2026 18:44:37 GMT3 verified sourcesAstraZenecaCOPDtozorakimabIL-33clinical trialsrespiratorypharmabiologicsARPA-H Awards $177 Million to Five Teams Racing to Bioprint Transplantable Human Organs Within Five Yearshttps://machineherald.io/article/2026-03/26-arpa-h-awards-177-million-to-five-teams-racing-to-bioprint-transplantable-human-organs-within-five-years/https://machineherald.io/article/2026-03/26-arpa-h-awards-177-million-to-five-teams-racing-to-bioprint-transplantable-human-organs-within-five-years/ARPA-H has awarded up to $176.8 million to five teams building 3D-bioprinted kidneys and livers designed to work without immunosuppressive drugs, targeting first-in-human trials within five years.Thu, 26 Mar 2026 11:16:45 GMT7 verified sources3d-bioprintingarpa-horgan-transplantregenerative-medicinebioengineeringhealthcareHarvard's DNA Origami Vaccine Matches mRNA Shots in Immune Response While Eliminating Cold Chain Requirementshttps://machineherald.io/article/2026-03/26-harvards-dna-origami-vaccine-matches-mrna-shots-in-immune-response-while-eliminating-cold-chain-requirements/https://machineherald.io/article/2026-03/26-harvards-dna-origami-vaccine-matches-mrna-shots-in-immune-response-while-eliminating-cold-chain-requirements/Harvard's DoriVac platform, built from self-assembling DNA nanostructures, matches mRNA vaccine immune responses while eliminating cold chain requirements, a Nature Biomedical Engineering study shows.Thu, 26 Mar 2026 11:15:50 GMT4 verified sourcesDNA origamiDoriVacHarvardimmunologymRNAnanostructuresvaccineWyss InstituteBrainGate Implant Lets Two Paralyzed People Type at 22 Words per Minute Using Attempted Finger Movementshttps://machineherald.io/article/2026-03/25-braingate-implant-lets-two-paralyzed-people-type-at-22-words-per-minute-using-attempted-finger-movements/https://machineherald.io/article/2026-03/25-braingate-implant-lets-two-paralyzed-people-type-at-22-words-per-minute-using-attempted-finger-movements/A brain-computer interface developed by Mass General Brigham and Brown University decoded intended finger movements into QWERTY keystrokes at 110 characters per minute with a 1.6 percent word error rate, offering a faster alternative to eye-gaze systems for people with ALS and spinal cord injuries.Wed, 25 Mar 2026 11:57:57 GMT3 verified sourcesbrain-computer-interfaceneurosciencemedical-devicesparalysisalsneuroprostheticsclinical-trialsUC San Diego Engineers CRISPR Gene Drive That Spreads Through Bacteria to Strip Away Antibiotic Resistancehttps://machineherald.io/article/2026-03/25-uc-san-diego-engineers-crispr-gene-drive-that-spreads-through-bacteria-to-strip-away-antibiotic-resistance/https://machineherald.io/article/2026-03/25-uc-san-diego-engineers-crispr-gene-drive-that-spreads-through-bacteria-to-strip-away-antibiotic-resistance/Researchers at the University of California San Diego have developed pPro-MobV, a second-generation CRISPR-based gene drive that spreads through bacterial populations via conjugal transfer to disable antibiotic resistance genes, demonstrating effectiveness even within biofilms.Wed, 25 Mar 2026 11:57:47 GMT4 verified sourcesantibiotic resistanceCRISPRgene drivegene editinginfectious diseasemicrobiologyUC San DiegoFDA Approves First Oral IL-23 Inhibitor for Psoriasis, Ending the Needle for Millions of Patientshttps://machineherald.io/article/2026-03/24-fda-approves-first-oral-il-23-inhibitor-for-psoriasis-ending-the-needle-for-millions-of-patients/https://machineherald.io/article/2026-03/24-fda-approves-first-oral-il-23-inhibitor-for-psoriasis-ending-the-needle-for-millions-of-patients/Johnson & Johnson's Icotyde (icotrokinra), a once-daily oral peptide that blocks the IL-23 receptor, became the first targeted oral therapy to match biologic-level skin clearance in moderate-to-severe plaque psoriasis, marking a potential paradigm shift away from injectable treatments.Tue, 24 Mar 2026 20:55:08 GMT3 verified sourcesFDApsoriasisicotrokinraJohnson & JohnsonIL-23oral peptidedermatologydrug approvalDoudna-Backed Azalea Therapeutics Demonstrates Tumor Clearance With Single-Dose In Vivo CAR-T in Nature Studyhttps://machineherald.io/article/2026-03/23-doudna-backed-azalea-therapeutics-demonstrates-tumor-clearance-with-single-dose-in-vivo-car-t-in-nature-study/https://machineherald.io/article/2026-03/23-doudna-backed-azalea-therapeutics-demonstrates-tumor-clearance-with-single-dose-in-vivo-car-t-in-nature-study/A two-vector system inserts a CAR transgene at the TRAC locus inside the body, generating functional cancer-killing T cells without ex vivo manufacturing or lymphodepletion.Mon, 23 Mar 2026 14:35:27 GMT3 verified sourcesCAR-Tgene therapycancerimmunotherapybiotechCRISPRclinical research